Plus Therapeutics Expands CNSide Assay Coverage to 127 Million with Medical Mutual Deal
Event summary
- Plus Therapeutics' subsidiary CNSide Diagnostics signed a regional coverage agreement with Medical Mutual effective July 1, 2026.
- The deal covers approximately 1.2 million people in Ohio and Kentucky, bringing total contracted coverage for the CNSide® CSF TCE assay to 127 million.
- Over 11,000 CNSide® tests have been performed since 2020 across more than 120 U.S. cancer institutions.
- The assay demonstrates high sensitivity (92%) and specificity (95%), influencing treatment decisions in 90% of cases.
The big picture
This agreement marks a significant step in the commercialization of CNSide® CSF TCE assay, aligning with the broader trend of precision diagnostics in oncology. The expansion of coverage to 127 million people underscores the growing recognition of the assay's clinical utility and its potential to influence treatment decisions for metastatic CNS cancer patients.
What we're watching
- Market Penetration
- How Plus Therapeutics will leverage this agreement to expand coverage beyond Ohio and Kentucky.
- Reimbursement Dynamics
- Whether the growing contracted coverage will translate into sustainable revenue growth for CNSide Diagnostics.
- Strategic Rebranding
- The impact of Plus Therapeutics' rebranding to Cerenome, Inc. on market perception and investor confidence.
Related topics